5-HT4 receptor agonist treatment of chronic constipation

Drugs of the Future

Volumn 36, Issue 6, 2011, Pages 447-454

  Vazquez Roque, M ^a   Camilleri, M ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; NARONAPRIDE; PRUCALOPRIDE; SEROTONIN 4 RECEPTOR; TEGASEROD; VELUSETRAG;

ABDOMINAL PAIN; BINDING AFFINITY; CARDIOVASCULAR DISEASE; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HEADACHE; HUMAN; IRRITABLE COLON; MAXIMUM PLASMA CONCENTRATION; NAUSEA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

EID: 84952985517     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.06.1594078     Document Type: Review

References (50)

1. Marquess, D., Fatheree, P.R., Turner, D.S., Long, D.D., Choi, S.-K., Goldblum, A.A., Genov, D. (Theravance, Inc.). Quinolinone-carboxamide compounds as 5-HT4 receptor agonists. EP 1735304, JP 2007535546, JP 2008174569, US 2005228014, US 2007281970, US 7375114, US 7728006, WO 2005100350.
2. Marquess, D., Fatheree, P.R., Turner, S.D., Long, D.D., Choi, S., Goldblum, A.A., Genov, D. (Theravance, Inc.). Quinolinone-carboxamide compounds as 5-HT4 receptor agonists. US 2007270457, US 7592355.
3. Marquess, D., Fatheree, P.R., Turner, S.D., Long, D.D., Choi, S., Goldblum, A.A., Genov, D. (Theravance, Inc.). Quinolinone-carboxamide compounds as 5-HT4, receptor agonists. US 2008176895, US 7763637.
4. Choi, S.-K., Fatheree, P., Goldblum, A.A., Jiang, L., Long, D.D., Marquess, D., Turner, S.D. (Theravance, Inc.). 5-HT4 receptor agonist compounds. US 2008255187, US 7534889.
5. Marquess, D., Fatheree, P.R., Turner, S.D., Long, D.D., Choi, S.-K., Goldblum, A.A., Genov, D. (Theravance, Inc.). Quinolinone-carboxamide compounds as 5-HT4 receptor agonists. US 2010285519.
6. Marquess, D., Fatheree, P.R., Turner, S.D., Long, D.D., Choi, S.-K., Goldblum, A.A., Genov, D. (Theravance, Inc.). Quinolone-carboxamide compounds as 5-HT4 receptor agonists. US 2010311979.
7. Choi, S.-K., Fatheree, P., Goldblum, A.A., Jiang, L., Long, D.D., Marquess, D., Turner, S.D. (Theravance, Inc.). 5-HT4 receptor agonist compounds. EP 1807422, JP 2008518965, US 2006100236, US 7399862, WO 2006052640.
8. Fatheree, P.R., Turner, S.D., Goldblum, A., Chao, R., Genov, D. (Theravance, Inc.). Crystalline form of a quinolinone-carboxamide compound. EP 1874766, JP 2008535848, US 2006229332, US 7728004, WO 2006108127.
9. McKinnell, R.M., Armstrong, S.R., Beattie, D.T. et al. A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. J Med Chem 2009, 52(17): 5330-43.
10. Genov, D., Lee, J., Liu, J. (Theravance, Inc.). Process for preparing intermediates to 5-HT4 receptor agonist compounds. EP 1984362, JP 2009526852, US 2007191355, WO 2007097976.
11. Higgins, P.D., Johanson, J.F. Epidemiology of constipation in North America: A systematic review. Am J Gastroenterol 2004, 99(4): 750-9. (Pubitemid 38612817)
12. Lembo, A., Camilleri, M. Chronic constipation. N Engl J Med 2003, 349(14): 1360-8.
13. Shah, N.D., Chitkara, D.K., Locke, G.R., Meek, P.D., Talley, N.J. Ambulatory care for constipation in the United States, 1993-2004. Am J Gastroenterol 2008, 103(7): 1746-53.
14. rd, Talley, N.J. Longitudinal direct medical costs associated with constipation in women. Aliment Pharmacol Ther 2011, 33(2): 251-60.
15. Sonnenberg, A., Koch, T.R. Physician visits in the United States for constipation: 1958 to 1986. Dig Dis Sci 1989, 34(4): 606-11. (Pubitemid 19122000)
16. Bongers, M.E., Benninga, M.A., Maurice-Stam, H., Grootenhuis, M.A. Health-related quality of life in young adults with symptoms of constipation continuing from childhood into adulthood. Health Qual Life Outcomes 2009, 7: 20.
17. Cuppoletti, J., Malinowska, D.H., Tewari, K.P., Li, Q.J., Sherry, A.M., Patchen, M.L., Ueno, R. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 2004, 287(5): C1173-83. (Pubitemid 39382875)
18. Ao, M., Venkatasubramanian, J., Boonkaewwan, C., Ganesan, N., Syed, A., Benya, R.V., Rao, M.C. Lubiprostone activates Cl(-) secretion via cAMPsignaling and increases membrane CFTR in the human colon carcinoma cell line, T84. Dig Dis Sci 2011, 56(2): 339-51.
19. Bijvelds, M.J., Bot, A.G., Escher, J.C., De Jonge, H.R. Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology 2009, 137(3): 976-85.
20. Johanson, J.F., Drossman, D.A., Panas, R., Wahle, A., Ueno, R. Clinical trial: Phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008, 27(8): 685-96. (Pubitemid 351406304)
21. Drossman, D.A., Chey, W.D., Johanson, J.F., Fass, R., Scott, C., Panas, R., Ueno, R. Clinical trial: Lubiprostone in patients with constipation- associated irritable bowel syndrome - Results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009, 29(3): 329-41.
22. Johanson, J.F., Morton, D., Geenen, J., Ueno, R. Multicenter, 4-week, doubleblind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008, 103(1): 170-7.
23. Gershon, M.D., Tack, J. The serotonin signaling system: From basic understanding to drug development for functional GI disorders. Gastroenterology 2007, 132(1): 397-414. (Pubitemid 46127672)
24. Tack, J., Broeckaert, D., Coulie, B., Janssens, J. The influence of cisapride on gastric tone and the perception of gastric distension. Aliment Pharmacol Ther 1998, 12(8): 761-6. (Pubitemid 28369883)
25. Prather, C.M., Camilleri, M., Zinsmeister, A.R., McKinzie, S., Thomforde, G. Tegaserod accelerates orocecal transit in patients with constipation- predominant irritable bowel syndrome. Gastroenterology 2000, 118(3): 463-8. (Pubitemid 30140843)
26. Quigley, E.M., Wald, A., Fidelholtz, J., Boivin, M., Pecher, E., Earnest, D. Safety and tolerability of tegaserod in patients with chronic constipation: Pooled data from two phase III studies. Clin Gastroenterol Hepatol 2006, 4(5): 605-13.
27. Evans, B.W., Clark, W.K., Moore, D.J. et al. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev 2007: CD003960.
28. Beattie, D.T., Smith, J.A., Marquess, D. et al. The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol 2004, 143(5): 549-60. (Pubitemid 39524272)
29. Johanson, J.F., Wald, A., Tougas, G. et al. Effect of tegaserod in chronic constipation: A randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol 2004, 2(9): 796-805. (Pubitemid 39200718)
30. Kamm, M.A., Muller-Lissner, S., Talley, N.J, et al. Tegaserod for the treatment of chronic constipation: A randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol 2005, 100(2): 362-72. (Pubitemid 40314521)
31. Frampton, J.E. Prucalopride. Drugs 2009, 69(17): 2463-76.
32. Camilleri, M., Kerstens, R., Rykx, A., Vandeplassche, L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008, 358(22): 2344-54. (Pubitemid 351749158)
33. Bouras, E.P., Camilleri, M., Burton, D.D., Thomforde, G., McKinzie, S., Zinsmeister, A.R. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001, 120(2): 354-60. (Pubitemid 32147632)
34. Emmanuel, A.V., Roy, A.J., Nicholls, T.J., Kamm, M.A. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002, 16(7): 1347-56.
35. Quigley, E.M., Vandeplassche, L., Kerstens, R., Ausma, J. Clinical trial: The efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - A 12-week, randomized, double-blind, placebocontrolled study. Aliment Pharmacol Ther 2009, 29(3): 315-28.
36. Camilleri, M., Vazquez-Roque, M.I., Burton, D., Ford, T., McKinzie, S., Zinsmeister, A.R., Druzgala, P. Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 2007, 19(1): 30-8. (Pubitemid 44952776)
37. Palme, M., Milner, P.G., Ellis, D.J., Marmon, T., Canafax, D.M. A novel gastrointestinal prokinetic, ATI-7505, increased spontaneous bowel movements (SBMS) in a phase II, randomized, placebo-controlled study of patients with chronic idiopathic constipation. Gastroenterology 2010, 138(5, Suppl. 1): S128-9.
38. Milner, P.G., Canafax, D.M., Palme, M., Morganroth, J. Results of a thorough QT study (ICH E14) testing a novel gastrointestinal prokinetic, ATI-7505, show no ECG effects at therapeutic and supratherapeutic doses. Gastroenterology 2010, 138(5, Suppl. 1): S164-5.
39. Manini, M.L., Camilleri, M., Goldberg, M. et al. Effects of velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 2010, 22(1): 42-9, e7-8.
40. Kim, D.Y., Camilleri, M. Serotonin: A mediator of the brain-gut connection. Am J Gastroenterol 2000, 95(10): 2698-709.
41. Hoyer, D., Hannon, J.P., Martin, G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002, 71(4): 533-54. (Pubitemid 34219205)
42. Hegde, S.S., Eglen, R.M. Peripheral 5-HT4 receptors. FASEB J 1996, 10(12): 1398-407.
43. Smith, J.A., Beattie, D.T., Marquess, D., Shaw, J.P., Vickery, R.G., Humphrey, P.P. The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 2008, 378(1): 125-37.
44. Smith, J., Beattie, D.T., Cuthbert, A.W. et al. TD-5108, a selective, high intrinsic activity 5-HT4 receptor agonist - In vitro profile at human recombinant 5-HT4 receptor splice variant and human isolated colon. Gastroenterology [Dig Dis Week (May 19-24, Washington, D.C.) 2007] 2007, 132(4, Suppl. 2): Abst W1222.
45. Beattie, D.T., Armstrong, S.R., Marquess, D., Shaw, J.-P., Smith, J.A., Humphrey, P.P. The in vivo preclinical profile of TD-5108, a selective, high intrinsic activity 5HT-4 receptor agonist. Gastroenterology [Dig Dis Week (May 19-24, Washington, D.C.) 2007] 2007, 132(4, Suppl. 2): Abst W1228.
46. Wong, S.L., Goldberg, M.R., Shaw, J.-P., Lanni, C., Ganju, J., Ballow, C.H., Kitt, M.M. In healthy subjects TD-5108, a selective high intrinsic activity 5-HT4 receptor agonist, shows dose-proportional pharmacokinetics and exhibits a profile consistent with once-caily dosing. Gastroenterology [Dig Dis Week (May 19-24, Washington, D.C.) 2007] 2007, 132(4, Suppl. 2): M-1156.
47. Manini, M.L., Wong, S.L., Goldberg, M.R. et al. TD-5108 pharmacokinetics and bowel function in health and constipation. Gastroenterology [Dig Dis Week (May 30-June 4, Chicago) 2009] 2009, Abst T1255.
48. Goldberg, M., Li, Y.P., Johanson, J.F, et al. Clinical trial: The efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - A 4-week, randomized, doubleblind, placebo-controlled, dose-response study. Aliment Pharmacol Ther 2010, 32(9): 1102-12.
49. Goldberg, M.R., Wong, S.L., Ganju, J., Li, Y.P., Ballow, C.H., Kitt, M.M. TD-5108, a selective 5-HT4 agonist with high intrinsic activity, shows immediate and sustained prokinetic activity in healthy subjects. Gastroenterology [Dig Dis Week (May 19-24, Washington, D.C.) 2007] 2007, 132(4, Suppl. 2): Abst 322.
50. Wang, L., McLeod, H.L., Weinshilboum, R.M. Genomics and drug response. N Engl J Med 2011, 364(12): 1144-53.